The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

On January 14, 2025, the Board approved a one-for-two-hundred (1:200) Reverse Split of the Common Stock. The Company anticipates that beginning with the opening of trading on February 10, 2025, the ...

China Universal Asset Management Co. Ltd. bought a new stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) during the fourth quarter, according to the company in its most recent 13F filing ...

Acrivon Therapeutics, Inc.’s ACRV share price has surged by 17.94%, which has investors questioning if this is right time to ...

Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...